Biotechnology company Alvotech SA (NASDAQ:ALVO) announced on Wednesday that it has acquired Ivers-Lee Group, a Swiss-based provider of pharmaceutical assembly and packaging services, to expand its global capacity ahead of key biosimilar launches in 2025.

Ivers-Lee, headquartered in Burgdorf, Switzerland, will continue as a separate legal entity but will be integrated into Alvotech's Technical Operations division.

The acquisition enhances Alvotech's flexibility and scale in delivering biosimilars worldwide, particularly in preparation for increased global demand. Ivers-Lee, a long-term partner of Alvotech, brings FDA-approved and GMP-licensed facilities, along with specialised capabilities including autoinjector and pre-filled syringe packaging.

Ivers-Lee also operates a business unit in Lörrach, Germany, which offers contract manufacturing services and clinical supplies. Ivers-Lee will continue serving its existing international clients while supporting Alvotech's production goals.

The acquisition reflects Alvotech's focus on operational scalability and quality, as it positions for sustained growth in the biosimilar market.